Takeda to evaluate Crescendo Biologics' Humabodies for immunotherapy
Takeda Pharmaceutical Company is to evaluate the use of Crescendo Biologics’ technology for a form of immunotherapy to treat cancer.
Babraham Research Campus-based Crescendo has a global, strategic collaboration and licence agreement with the Japanese pharma giant, dating from October 2016 and worth up to a potential $754million plus royalties.
Last November, Takeda took an early exclusive license, enabling it to direct Crescendo’s Humabodies towards one of its oncology targets.
Now it has been confirmed that it will evaluate their use in the development of novel CAR-T therapeutics.
CAR-T cell therapy uses a patient’s own T cells, which form part of the immune system. They are collected in blood and altered to produce structures called chimeric antigen receptors (CARs) on their surface.
Dr Peter Pack, CEO of Crescendo, said: “We’re pleased to see the research Takeda is undertaking with our Humabody technology.
“Their desire to explore the Humabody technology in a CAR-T setting presents an exciting opportunity to evaluate whether Humabodies can address the issues that exist with other CAR-T targeting approaches.”
Crescendo’s Humabodies are a class of small, protein therapeutics based on a specific building block of a human antibody known as the VH domain. They can be configured to target multiple targets.
Takeda’s research will investigate the unique properties of Humabody VHs for tumour targeting of CAR-Ts. Its licensing of the technology means it can evaluate a large number of different VHs towards the same target to identify the format that delivers enhanced safety and functionality.
Crescendo was joint winner of Biotech Company of the Year at the Cambridge Independent Science and Technology Awards 2018.